- Home
- ZVIA vs CNTB Comparison
ZVIA vs CNTB Comparison
Compare ZVIA & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZVIA | CNTB |
|---|---|---|
| Founded | 2007 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 126.3M | 140.4M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ZVIA | CNTB |
|---|---|---|
| Price | $1.22 | $0.97 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | $3.96 | ★ $5.88 |
| AVG Volume (30 Days) | 362.9K | ★ 1.9M |
| Earning Date | 11-04-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 55.88 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $161,259,000.00 | $64,000.00 |
| Revenue This Year | $8.02 | $11,292.49 |
| Revenue Next Year | $6.05 | $114.35 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 4.01 | N/A |
| 52 Week Low | $1.11 | $0.98 |
| 52 Week High | $2.78 | $3.82 |
Technical Indicators
Market Signals| Indicator | ZVIA | CNTB |
|---|---|---|
| Relative Strength Index (RSI) | 36.29 | 40.59 |
| Support Level | $1.13 | $1.06 |
| Resistance Level | $1.50 | $2.80 |
| Average True Range (ATR) | 0.07 | 0.13 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 9.23 | 12.10 |
Price Performance
Historical ComparisonAbout ZVIA Zevia PBC
Zevia PBC is a beverage company disrupting the liquid refreshment beverage industry through refreshing, zero-calorie, zero-sugar, naturally sweetened beverages that are all Non-GMO Project Verified. It offers a platform of products that include a variety of flavors across Soda, Energy Drinks, Organic Tea, Mixers, Kidz drinks, and Sparkling Water. Its products are distributed across the U.S. and Canada through a network of retailers in the food, drug, mass, natural, and e-commerce channels. The company derives a majority of its revenue from the United States.
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.